Vs 22 , p = 0.011) and a higher average BMI (20 ?4 vs 23 ?4, p <0.0…

Vs 22 , p = 0.011) and a higher average BMI (20 ?4 vs 23 ?4, p 1-(4-Bromo-2-pyridyl)piperazine vs 91 , p Methyl 2-((4-nitro-1h-pyrazol-1-yl)methyl)benzoate with intratracheal intubation in group NS was significantly higher than that in group S. The duration of mechanical ventilation with intratracheal intubation was significantly shorter in group S (11 ?17 vs 23 ?38 days, p = 0.038).Hemorrhagic complicationsHemorrhagic complications occurred in two patients (2.0 ). Of the two patients, one who received rTM combined with gabexate mesilate for 2 days developed bleeding of the ocular fundus. Another patient with cirrhosis PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/24083752 (Child-Pugh classification B) developed a respiratory tract hemorrhage. Multivariate logistic regression analysis of outcomes was performed (Table 3).Multivariate logistic regression analysis for outcomeAt the start of rTM administration, the APACHEII and SOFA scores were significantly lower in group S asThe duration of time between the onset of disease causing DIC and rTM administration, the APACHEII score, the SOFA score, and CRRT use were selected asYatabe et al. Journal of Intensive Care 2014, 2:49 http://www.jintensivecare.com/content/2/1/Page 4 ofTable 2 Severity of illness and treatment for disseminated intravascular coagulationGroup S s12325-016-0451-1 (n = 57) rTM treatment duration, days, mean ?SD 6.1 ?2.9 Dose of rTM, U/kg/day, mean ?SD PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/13485127 Duration from onset to rTM, n ( ) 0 days 1 day 2 days APACHEII at start of rTM, mean ?SD SOFA at start of rTM, mean ?SD DIC score at start of rTM, mean ?SD DIC score at end of rTM, mean ?SD 23 (40) 19 (33) 15 (26) 26 ?6 9.5 ?4.2 5.2 ?1.8 3.0 ?2.0 9 (20) 13 (30) 22 (50) 32 ?6 13.4 ?3.6 5.6 ?1.7 4.9 ?1.9 43 (98) 23 ?38 40 30 21 37 18 <0.001 <0.001 0.20 <0.001 0.01 0.038 <0.001 0.60 0.83 0.29 0.11 Group NS p value (n = 44) 6.4 ?8.4 0.78 0.083 0.Table 3 Multivariate logistic regression analysis for outcomeReference Gender APACHEII at start of rTM rTM 1 day rTM 2 days Female 0 days 0 days Adjusted odds ratio 3.39 1.18 1.95 3.36 95 confidence interval 1.19?.64 1.09?.29 0.57?.62 1.03?0.92 p value 0.022 <0.001 0.29 0.345 ?108 308 ?Hosmer-Lemeshow test (chi-square = 15.13, degrees of freedom = 8, p = 0.057). C-statistics = 0.82. APACHEII Acute Physiology and Chronic Health Evaluation II, rTM recombinant thrombomodulin. rTM x day Duration from t.